



ANNUAL REPORT

2025

TABLE OF CONTENTS

02	PRESIDENT'S MESSAGE
04	AMP STRATEGIC PLAN
05	2025 BOARD OF DIRECTORS
06	ORGANIZATIONAL RELATIONSHIPS
08	ADVANCING MOLECULAR MEDICINE
09	INNOVATION & IMPROVED PATIENT CARE
11	MEMBERSHIP
12	ANNUAL MEETING & CONFERENCES
13	EDUCATION & PROFESSIONAL DEVELOPMENT
14	FINANCES

Dear Colleagues, Patients and Friends,

It is an honor to reflect on another remarkable year for the Association for Molecular Pathology. Together, we have strengthened our community, expanded our global reach and advanced our shared mission to improve patient care through excellence in molecular diagnostics.

The defining moment of 2025 was the landmark victory in our case against the U.S. Food and Drug Administration. The U.S. District Court's decision vacated the FDA's final rule to regulate LDTs as medical devices, an overstep that would have gravely impacted AMP members, laboratories and, perhaps most importantly, patients. The support from our members, partners, staff and legal team in this fight was invaluable, and we are deeply grateful. Moving forward, our advocacy efforts will continue to uphold policies based on science that uphold the highest standards of patient care.

We made notable strides in expanding our international presence this year. We held our first AMP Middle East meeting in April in Abu Dhabi, and we welcomed two organizations – representing South Korea and Australasia – as international affiliates.

At our annual AMP meeting in Boston, members and others in the molecular diagnostics community presented cutting-edge insights, shared best practices and expanded their networks. We received a record number of abstract and case study submissions, which underscores how highly the community regards our annual meeting.

PRESIDENT'S MESSAGE

03

We remained deeply committed to building and sustaining a strong, skilled molecular diagnostics workforce through high-quality educational programs, practical resources and professional-development opportunities. By equipping current and future professionals with the knowledge and tools they need to succeed, we help laboratories continue to deliver accurate, timely and clinically meaningful results.

AMP's leadership in clinical practice is as strong as ever. Through the development of authoritative guidelines, consensus papers and best-practice recommendations, in 2025 we continued to provide the standards and resources that laboratories rely on to deliver high-quality testing. These materials support consistency, accuracy and clinical utility, ultimately improving patient care.

None of these accomplishments would have been possible without the dedication, expertise and passion of our members. Thank you for your continued commitment to advancing molecular medicine and improving lives.

Sincerely,

Jane S. Gibson, Ph.D., FACMG

President, AMP (2025)
University of Central Florida
College of Medicine



Mission

The Association for Molecular Pathology is a not-for-profit scientific society that advances the clinical practice, science and excellence of molecular and genomic laboratory medicine through education, innovation and advocacy to enable highest quality health care.

Vision

The Association for Molecular Pathology provides global expertise in molecular testing that drives patient care

AMP's strategic plan is dynamic.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's mission, vision and core principles.

Core Principles

●
Advocacy that advances the field and practice of molecular pathology, protects patients and improves the adoption of innovative technologies and tests

●
Quality health care through excellence in clinical molecular testing

●
Fostering a diverse and inclusive global community of molecular pathology professionals

●
Innovation to transform patient care

●
Collaboration to advance molecular pathology and improve equity in the delivery of molecular laboratory testing

2025

BOARD OF DIRECTORS

05

President

Jane S. Gibson., Ph.D.

President-Elect

Aaron D. Bossler, M.D., Ph.D.

Past President and Nominating Committee
Chair

Maria E. Arcila, M.D.

Secretary-Treasurer and Finance Committee
Chair

Yasmine M.N. Akkari, Ph.D.

Clinical Practice Committee Chair

Alanna Church, M.D.

Early Career Member

Adam Fisch, M.D., Ph.D.

Early Career Member

Emilia Calvaresi, M.D. Ph.D.

Economic Affairs Committee Chair

Jay Patel, M.D.

International Affairs Committee Chair

Rami Mahfouz, M.D MPH.

Membership Affairs Committee Chair
Jennifer Morrisette, Ph.D.

Professional Relations Committee Chair
Eric Konnick, M.D., M.S.

Program Committee Chair
Somak Roy, M.D.

Publications Committee Chair
Patricia Tsang, M.D.

Training & Education Committee Chair
Marjorie David, M.D., M.S.

Genetics Subdivision Chair
Kristy Crooks, Ph.D., FACMG

Hematopathology Subdivision Chair
Rena R. Xian, M.D.

Infectious Diseases Subdivision Chair
Joseph D.C. Yao, M.D.

Informatics Subdivision Chair
**Julie Woolworth Hirschhorn, Ph.D.,
HCLD(ABB)**

Solid Tumors Subdivision Chair
Anthony N. Snow, M.D.

Chief Executive Officer
Laurie Menser, CAE



In support of our mission and core principle of collaboration, AMP maintains membership in and formal representation with a range of professional societies, coalitions and advocacy groups working to advance molecular pathology, improve patient access to testing and promote equity in care. The list below highlights key organizations but is not exhaustive.

AMP maintains membership in the following organizations:

- American College of Surgeons
American Joint Committee on
Cancer (AJCC)
- Association for Pathology
Informatics (API)
- BLOODPAC
- Cancer Leadership Council (CLC)
- Federation of American Societies
for Experimental Biology (FASEB)
- From Testing to Targeted
Treatments (FT3)

- Inter-Society Coordinating
Committee for Practitioner
Education in Genomics (ISCC)
- Intersociety Council for Pathology
Information (ICPI) – Associate
Member
- Intersociety Pathology Council
(IPC)
- Personalized Medicine Coalition
(PMC)

AMP has formal representation in many groups, including, but not limited to, the following:

- American Board of Pathology (ABP) – Cooperating Society
- College of American Pathologists (CAP)
 - Pathology Coding Caucus (PCC) – Representative
 - Molecular Oncology Committee – Representative
 - Pathology and Laboratory Quality Center for Evidence-Based Guidelines Expert Panels – Representatives
- Centers for Disease Control and Prevention
 - Surge Capacity Memorandum of Understanding Partners
 - Forum on Adoption of Standards for Laboratory Data Exchange and Interoperability

- ClinGen Somatic Cancer Clinical Domain Workgroup – Representative
- Food and Drug Administration
 - Network of Experts
 - Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD) – Representative

- Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Steering Committees – Representatives
- Intersociety Council for Pathology Information (ICPI) – Associate Member
- National Academies Roundtable on Genomics and Precision Health – Sponsor
- National Institute of Standards and Technology Genome in A Bottle Consortium – Steering Committee
- Test Renaming for Understanding and Utilization for Laboratory Test Names (TRUU-Lab) – Representatives

AMP pursued a wide range of economic and policy initiatives in 2025. Key moments included:

- Winning our lawsuit against the FDA on its rule for laboratory-developed test procedure regulation
- Holding 34 Capitol Hill meetings, including the first in-person Hill Day since 2019
- Publishing a prior authorization position statement to guide policy and payer practices
- Participating in the Clinical Laboratory Fee Schedule annual payment determination process

- Engaging the U.S. Centers for Medicare & Medicaid Services on coverage and pricing topics relevant to AMP membership
- Issuing 28 position statements and public comments on key policy issues
- Developing an animated video explaining screening versus diagnostic testing in hepatitis

For more information about AMP's advocacy efforts, please visit our [Position Statements & Letters webpage](#).

AMP supports and promotes genomic medicine and informatics through evidence-based practice guidelines and peer-reviewed publications. AMP publishes in *The Journal of Molecular Diagnostics*, and all guidelines are freely available at amp.org.

The following were published in 2025:

Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, Association of Cancer Care Centers, and College of American Pathologists
(DOI: [10.1016/j.jmoldx.2025.05.003](https://doi.org/10.1016/j.jmoldx.2025.05.003))

Considerations for SARS-CoV-2 Genomic Surveillance: A Joint Consensus Recommendation of the Association for Molecular Pathology and Association of Public Health Laboratories
(DOI: [10.1016/j.jmoldx.2024.09.005](https://doi.org/10.1016/j.jmoldx.2024.09.005))

Clinical practice collaboration is both a core value and daily activity:

30+ representatives from **16 different professional organizations** are currently serving on AMP's **12+ active working groups**.

50+ organizations have invited AMP to collaborate with **100+ AMP member external representatives** providing expertise to **75+ projects, committees or workgroups**.

AMP non-guideline journal publications do not make new clinical practice recommendation statements, perform systematic reviews, or grade evidence. Regardless, these publications reflect an appropriate review of published clinical and scientific evidence and subject matter expertise.

The following were published in 2025:

Developing Consensus for a More Provider-Friendly Next-Generation Sequencing Molecular Biomarker Report: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists
(DOI: [10.1016/j.jmoldx.2025.08.011](https://doi.org/10.1016/j.jmoldx.2025.08.011))

Development of a Body of Knowledge for the Clinical Bioinformatician: Perspectives from the Association for Molecular Pathology's Clinical Bioinformatician Body of Knowledge Steering Committee
(DOI: [10.1016/j.jmoldx.2024.12.002](https://doi.org/10.1016/j.jmoldx.2024.12.002))

Clinical Bioinformatician Body of Knowledge – Molecular Diagnostics Core: A Report of the Association for Molecular Pathology
(DOI: [10.1016/j.jmoldx.2025.03.006](https://doi.org/10.1016/j.jmoldx.2025.03.006))

Clinical Bioinformatician Body of Knowledge – Bioinformatics and Software Core: A Report of the Association for Molecular Pathology
(DOI: [10.1016/j.jmoldx.2025.04.008](https://doi.org/10.1016/j.jmoldx.2025.04.008))

Clinical Bioinformatician Body of Knowledge – Clinical Laboratory Regulation and Data Security Core: A Report of the Association for Molecular Pathology
(DOI: [10.1016/j.jmoldx.2025.04.003](https://doi.org/10.1016/j.jmoldx.2025.04.003))

Interested in collaborating with AMP?
Contact our clinical affairs team at AMPClinicalPractice@amp.org.

MEMBERSHIP


Our community consists of healthcare professionals who are committed to helping people. Our field is best served by amplifying diverse voices in our community and including representation from across the spectrum of our community in everything we do. We work together to address inequities for patients.

New members welcomed in 2025: **789**

Total membership: **3,145** members across **77** countries

Primary degrees held by AMP members:

466
M.D., Ph.D.




937
M.D.

918
Ph.D.

813
Bachelor's, Master's and other degrees

AMP membership by type:

1,041
Associate members
(students, residents and fellows)



257
Technologist members

1,813
Regular members

34
Emeritus members
(retired)

International Affiliates:

- The Hong Kong Society for Molecular Diagnostic Sciences
- The Molecular Pathology Association of India
- The Korean Society for Laboratory Medicine
- The German Society of Pathology
- Brazilian Society of Clinical Pathology and Laboratory Medicine
- The Italian Society of Pathology and Translational Medicine
- American University of Beirut Medical Center
- Middle East Molecular Biology Sources
- Association Iberoamericana de Patologia Molecular
- The Korean Society for Genetic Diagnostics
- Australasian Molecular Pathology Society

ANNUAL MEETING & CONFERENCES

12

The AMP 2025 Annual Meeting & Expo was held in Boston in November.

We welcomed more than 1,850 attendees and nearly 200 exhibiting companies for a dynamic week of scientific dialogue, learning and community-building. More than 500 poster presentations enlivened the expo floor, highlighting innovative work from laboratory professionals around the world. Abstracts from those presentations are freely available in AMP's official journal, The Journal of Molecular Diagnostics (DOI: [10.1016/j.jmoldx.2025.10.005](https://doi.org/10.1016/j.jmoldx.2025.10.005)).



The inaugural AMP Middle East was held in Abu Dhabi, United Arab Emirates, in April.

Over two days, attendees gathered to engage with leaders across the field of molecular pathology, connect with peers and participate in lively panels, spotlights and sessions. This first-of-its-kind meeting also fostered discussion about how molecular pathology advances address the unique clinical and diagnostic challenges faced in the Middle East.



AMP's education portfolio continued to grow in 2025 through expanded offerings of live webinars, on-demand recorded content and self-paced courses and certificate programs on AMPED™.

We published more than 50 hours of new recorded content this year, including 17 webinars and an updated MGP Review Course, and more than 40 hours of material from the 2025 annual meeting.

Other points of pride:

- More than **98,000 users** visited AMPED™, resulting in more than **460,000 page views**.
- > 300 hours of content available on AMPED™
- **100%** of 2025 MGP diplomates used AMP's Fellowship In-Service Exam and **over 90%** of 2025 MGP diplomates used other AMP education resources on AMPED™
- The 2025 MGP Review Course attracted **over 100 live registrants** from all over the world.
- Provided support to the MGP Program Directors Council for the second NRMP MGP Fellowship Match for MGP programs nationwide. Fellowship program participation **increased from 79% (2024) to 88% (2025)**.

We greatly appreciate the volunteers, partners and corporate sponsors who enable AMP's essential education initiatives.

FINANCIAL STATEMENT

14

STRATEGIC INITIATIVE REVENUE OVER EXPENSES	2025	2024	2023
Advocacy	\$ (852,082.68)	\$ (1,826,575.74)	\$ (736,954.74)
Communications & Outreach	\$ (136,074.50)	\$ (160,479.81)	\$ (193,014.32)
Education	\$ 1,768,942.72	\$ 1,584,343.97	\$ 1,712,266.90
Innovation & Improved Patient Care	\$ (533,374.42)	\$ (469,428.29)	\$ (560,820.26)
Membership & Management Services	\$ (516,820.88)	\$ (360,816.78)	\$ (324,519.47)
Excess Revenue Over Expenses	\$ (269,409.76)	\$ (1,232,956.65)	\$ (103,041.89)

Please note that in 2024 the AMP Board of Directors approved a budget deficit to pay for AMP's successful lawsuit against the U.S. Food and Drug Administration over its final rule on oversight of laboratory developed testing procedures.



**6120 EXECUTIVE BOULEVARD
SUITE 700
ROCKVILLE, MARYLAND,
20852**

AMP.ORG